The filing comes as Novo fights tooth-and-nail with rival Lilly to regain its footing at the top of the weight loss market.
Novartis has discontinued two undisclosed programs under its current partership with Voyager, the biotech announced last ...
Participants in a Phase III trial who switched to Eli Lilly’s orforglipron after 72 weeks of treatment with Wegovy or ...
The tickets could go to the lipid-lowering pill enlicitide decanoate and the antibody-drug conjugate sacituzumab tirumotecan, ...
The Greater Philadelphia life sciences ecosystem has over 1,200 life sciences establishments, including 450 biotech research ...
Clarity on employment terms is essential to protect careers. In this column, Kaye/Bassman’s Michael Pietrack speaks to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback